Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0X6TF
|
||||
Former ID |
DNC014475
|
||||
Drug Name |
(+/-)-threo-Ritalinol
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C13H19NO
|
||||
Canonical SMILES |
C1CCNC(C1)C(CO)C2=CC=CC=C2
|
||||
InChI |
1S/C13H19NO/c15-10-12(11-6-2-1-3-7-11)13-8-4-5-9-14-13/h1-3,6-7,12-15H,4-5,8-10H2/t12-,13-/m1/s1
|
||||
InChIKey |
IKNCLLOBJQVKNP-CHWSQXEVSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Sodium-dependent dopamine transporter | Target Info | Inhibitor | [1] | |
KEGG Pathway | Dopaminergic synapse | ||||
Parkinson's disease | |||||
Cocaine addiction | |||||
Amphetamine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
Parkinson disease | |||||
Dopamine receptor mediated signaling pathway | |||||
Pathway Interaction Database | Alpha-synuclein signaling | ||||
Reactome | Na+/Cl- dependent neurotransmitter transporters | ||||
WikiPathways | Monoamine Transport | ||||
NRF2 pathway | |||||
Dopaminergic Neurogenesis | |||||
Parkinsons Disease Pathway | |||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
Neurotransmitter Clearance In The Synaptic Cleft | |||||
References | |||||
REF 1 | Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. Epub 2010 Aug 19.Quantitative structure-activity relationship studies of threo-methylphenidate analogs. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.